MAPK 13 inhibitor (Washington University)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameMAPK 13 inhibitor (Washington University)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Actionp38-δ mitogen-activated protein kinase degraders
Targetsp38-δ mitogen-activated protein kinase
Therapy Area/IndicationsRespiratory Tract Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesWashington University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWashington University
Active IndicationsN/A
Inactive IndicationsRespiratory Tract Diseases

Other Information

ATC CodeN/A
Related LinksN/A